The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Revised Retinopathy Screening Guidelines State Risks Linked to Hydroxychloroquine, Chloroquine

Revised Retinopathy Screening Guidelines State Risks Linked to Hydroxychloroquine, Chloroquine

November 16, 2016 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Kelly Weselman, MD, FACR, WellStar Rheumatology, Smyrna, Ga., said the guidelines will likely result in some dosing adjustments for patients whose ideal and real body weight differ significantly.

You Might Also Like
  • Hydroxychloroquine Retinopathy Still Alive and Well
  • Ocular Disease Monitoring Critical to Avoid Retinal Toxicity from Hydroxychloroquine
  • Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus
Explore This Issue
November 2016
Also By This Author
  • REMS Required

Petros Efthimiou, MD, FACR, associate chief of rheumatology, New York Methodist Hospital, and associate professor of clinical medicine and rheumatology, Weill Medical College of Cornell University, New York, may ask patients to split tablets or use variable dosing by alternating or skipping doses on some days. “This way, hydroxychloroquine will be dosed according to the guidelines and retinal toxicity can be minimized, provided a careful ophthalmologic monitoring is also in place,” he said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Some rheumatologists request that patients on HCQ and CQ get screened every year; the guidelines show that this is not usually necessary until five years of use. In fact, Dr. Weselman will change her recommendation for patients based on the update. “I will have some reassurance that such annual exams could be delayed until the patient has been maintained on the medication for five years,” she said.

All patients beginning long-term HCQ or CQ therapy should have a baseline eye exam in the first year of starting the drug.

Ophthalmologist Frederick W. Fraunfelder, MD, MBA, Roy E. Mason and Elizabeth Patee Mason Distinguished Professor, and chairman, ophthalmology, University of Missouri Health System, Columbia, focused on the value of making sure patients have a screening eye examination within the first year of treatment. “Any symptoms of visual loss or disturbance should be followed promptly by an ophthalmologist,” he said.

Dr. Efthimiou stressed the important role of HCQ and CQ for certain patients. “I want to emphasize how valuable antimalarial drugs are in the treatment of our diseases, especially SLE, where hydroxychloroquine is the cornerstone drug. While it is important to diagnose retinal toxicity, this has to be done carefully, using objective measures and confirmatory methods,” he said.

“Making a decision to stop this medication can present major problems for managing the underlying inflammatory disease,” Dr. Weselman said. However, she believes the guidelines strive for balance in stating the importance of the medications but also recommending further testing for verification of certain findings before making a decision to stop the medication.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Ophthalmologist Adrian W. Jachens, MD, EyeCare 20/20, East Hanover, N.J., applauded the fact that specific screening tools are recommended for annual screening. “SD-OCT is much more prevalent in ophthalmologists’ practices, so it makes sense to make it part of the required screening,” he said.

Based on the new guidelines, Dr. Jachens will ask patients using HCQ or CQ if they have any renal disease or have used tamoxifen, to help guide how often they should return after baseline screening.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: American Academy of Ophthalmology, chloroquine, eye, guideline, HYDROXYCHLOROQUINE, ocular, patient care, recommendation, retinopathy, rheumatologist, risk, screening, usage, visionIssue: November 2016

You Might Also Like:
  • Hydroxychloroquine Retinopathy Still Alive and Well
  • Ocular Disease Monitoring Critical to Avoid Retinal Toxicity from Hydroxychloroquine
  • Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus
  • Hydroxychloroquine Risk-Benefit Discussion, & a Handy Dosage App

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.